Meeting
2015 ASCO Annual Meeting
Vaccination of MSI-H colorectal cancer patients with frameshift peptide antigens: A phase I/IIa clinical trial.
Authors
Matthias Kloor
University of Heidelberg, Heidelberg, Germany
Matthias Kloor , Miriam Reuschenbach , Julia Karbach , Mohammed Rafiyan , Salah-Eddin Al-Batran , Claudia Pauligk , Elke Jaeger , Magnus von Knebel Doeberitz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Vaccines
Clinical Trial Registration Number
NCT01461148
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3020)
DOI
10.1200/jco.2015.33.15_suppl.3020
Abstract #
3020
Poster Bd #
346
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Attitudes toward prevention options in Lynch syndrome (LS): Comparing frameshift peptide vaccination (FSPVAX), colonoscopy (COLO), and aspirin (ASA) chemoprevention.
First Author: Michael J. Hall
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.
First Author: Lin Shen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Perceptions of cancer prevention options for Lynch syndrome (LS) in a multi-national convenience sample.
First Author: Michael J. Hall
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Trial in progress: A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).
First Author: Joleen M. Hubbard